Patient Guide: A Multi-part, Adaptive Phase 1, First Time in Human Study in Healthy Volunteers to Assess Safety, Tolerability and Pharmacokinetics (PK) Following Single Ascending Dose (SAD) and Multiple Ascending Doses (MAD) of MTX325, Including Option to Assess: a Single Dose in Elderly Participants; Multiple Doses in Patients With Parkinson's Disease (PD); Central Nervous System (CNS) Penetration, Biodistribution, and Biomarkers; and the Effect of Food on PK.

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 4 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT07630545
Status: 🟢 Enrolling Now
Condition: Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease, Early Stage Parkinson's Disease
Phase: PHASE1

Find a Study Location Near You

This study is available at 4 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Liverpool,
  • London,
  • Merthyr Tydfil,
  • • And 1 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily